T. Rowe Price Associates
OLMA icon

T. Rowe Price Associates’s Olema Pharmaceuticals OLMA Stock Holding History

T. Rowe Price Associates’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.6M Buy
1,182,836
+86,801
+8% +$1.93M ﹤0.01% 1079
2025
Q4 		$27.4M Buy
1,096,035
+1,064,254
+3,349% +$18.9M ﹤0.01% 981
2025
Q3 		$312K Buy
31,781
+1,920
+6% +$11.5K ﹤0.01% 2588
2025
Q2 		$128K Buy
29,861
+12,325
+70% +$55K ﹤0.01% 2843
2025
Q1 		$66K Sell
17,536
-8,576
-33% -$43.1K ﹤0.01% 2894
2024
Q4 		$153K Sell
26,112
-5,346
-17% -$53.4K ﹤0.01% 2763
2024
Q3 		$376K Buy
31,458
+216
+0.7% +$2.76K ﹤0.01% 2376
2024
Q2 		$339K Buy
31,242
+4,991
+19% +$54.1K ﹤0.01% 2368
2024
Q1 		$298K Buy
26,251
+1,486
+6% +$19.2K ﹤0.01% 2436
2023
Q4 		$348K Sell
24,765
-14,081
-36% -$189K ﹤0.01% 2333
2023
Q3 		$480K Sell
38,846
-22,007
-36% -$224K ﹤0.01% 2122
2023
Q2 		$550K Buy
60,853
+2,553
+4% +$15.4K ﹤0.01% 2085
2023
Q1 		$203K Sell
58,300
-10,200
-15% -$41.6K ﹤0.01% 2521
2022
Q4 		$168K Hold
68,500
– – ﹤0.01% 2586
2022
Q3 		$190K Hold
68,500
– – ﹤0.01% 2561
2022
Q2 		$279K Sell
68,500
-2,372
-3% -$7.52K ﹤0.01% 2474
2022
Q1 		$302K Buy
70,872
+700
+1% +$3.86K ﹤0.01% 2545
2021
Q4 		$657K Buy
+70,172
New +$1.45M ﹤0.01% 2257
2021
Q3 		– Sell
-8,623
Closed -$241K – 2975
2021
Q2 		$241K Buy
8,623
+173
+2% +$4.92K ﹤0.01% 2660
2021
Q1 		$280K Buy
+8,450
New +$362K ﹤0.01% 2588

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

T. Rowe Price Associates's OLMA Position: Q1 2026 in Review

T. Rowe Price Associates increased its Olema Pharmaceuticals (OLMA) stake by 7.9% in Q1 2026, buying an estimated $1.93M and bringing the position to 1,182,836 shares worth $17.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1079.

T. Rowe Price Associates first reported a position in OLMA in Q1 2021 and has held it in 20 quarters since. The position peaked at $27.4M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • T. Rowe Price Associates held 1,182,836 shares of Olema Pharmaceuticals worth $17.6M as of Q1 2026.
  • T. Rowe Price Associates bought 86,801 Olema Pharmaceuticals shares in Q1 2026, an estimated $1.93M.
  • Olema Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1079 holding.
  • T. Rowe Price Associates first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Olema Pharmaceuticals position peaked at $27.4M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.